PI Industries: consolidated PAT sinks 39% YoY as revenue falls 10%, margins compress

PI Industries' consolidated PAT for Q1 FY27 (quarter ended June 30, 2026) fell 39.0% YoY to ₹244.2 Cr from ₹400.0 Cr, on revenue down 10.4% YoY to ₹1,702.3 Cr from ₹1,900.5 Cr. Neither this quarter nor the year-ago quarter carried exceptional items, so the decline is fully underlying rather than one-off-driven. Sequentially PAT rose 22.0% and revenue 8.8% off a seasonally soft Q4 FY26, but per the primary YoY read this is a weak quarter, not a rebound.

Gross costs held broadly steady — cost of materials consumed was 40.1% of revenue versus 39.9% a year ago — so the margin damage sits below the gross line. Operating margin (EBITDA/revenue) compressed to roughly 21.6% from 27.3% YoY (-573 bps), and net margin (PAT/total income) fell to 13.8% from 20.1% (-631 bps). The squeeze came from employee costs up 12.3% YoY and finance cost more than doubling (₹7.9 Cr vs ₹3.9 Cr) against a shrinking revenue base — classic operating deleverage. By segment, agro chemicals revenue fell 9.8% YoY to ₹1,648.8 Cr with segment PBT down 32.2% to ₹383.5 Cr; the smaller pharma (CDMO) segment saw revenue drop 25.0% YoY to ₹54.2 Cr and its pre-tax loss widen to ₹(81.6) Cr from ₹(76.0) Cr.

The stock went into the print at ₹2,730, up 6.3% over the past month of trading.

EPS (consolidated, basic) ₹16.10 vs ₹26.37 a year ago and ₹13.20 last quarter

No specific Street consensus for this quarter's numbers turned up in search; brokerages had already trimmed FY26E/FY27E estimates and flagged a cautious near-term outlook on prolonged export destocking ahead of the print (Business Standard, June 2026), so vsStreet is marked unknown rather than guessed. On guidance, management's Q4 FY26 call had projected positive FY27 revenue growth led by an H2-weighted export recovery, gross margins held at FY26 levels, and an effective tax rate up to 24%. This quarter met the margin leg and sits right at the ETR ceiling (consolidated ETR 24.1%), but the growth leg hasn't shown up yet — revenue is still contracting YoY, consistent with a recovery management itself pushed to the second half rather than an outright guidance miss. No management press release accompanied this filing to cross-check tone against the numbers.